ISSN: 1859 - 2872
Comparison of Helicobacter pylori eradication rate of levofloxacin-containing quadruple therapy with levofloxacin-containing triple therapy in patients failed the standard triple therapy
Main Article Content
Keywords
Abstract
Summary
Objective: After failure of PPI-clarithromycin-amoxicillin triple therapy, a levofloxacin containing triple or quadruple therapy are recommended as a second-line treatment. There have been no studies to compare the efficacy of levofloxacin-containing quadruple therapy with levofloxacin-containing triple therapy for the treatment of Helicobacter pylori (H. pylori) infection after failure of PPI-clarithromycin-amoxicillin triple therapy in our country. Therefore, we conducted this study to compare the eradication rate, adverse events and compliance of two regimens. Subject and method: The study was carried out on 128 patients who fail initial PPI-clarithromycin-amoxicillin triple therapy. 62 patients received a levofloxacin-based quadruple therapy, and 66 patients received a levofloxacin-based triple therapy. Four to eight weeks after completion of therapy, H. pylori status was rechecked by clotest or C13 urea-breath test. The primary outcome was the eradication rate in the intention-to-treat (ITT) and per protocol (PP) analysis. Result: The eradication rates of the levofloxacin containing quadruple therapy was higher than that of levofloxacin containing triple therapy (90.0% vs 83.1% using PP analysis and 82.2% vs 77.8%, using ITT analysis, p<0.05), side effects occurred in patients treated by two regimens were not different (p>0.05). The compliance rate of 90% or greater of two regimens were more than 90%. Conclusion: Helicobacter pylori eradication rate of levofloxacin containing quadruple regimen was higher than that of levofloxacin containing triple regimen in patients had failed PPI-clarithromycin-amoxicillin triple therapy
Keywords: Levoflocaxin containing triple regimen, levoflocaxin containing quadruple regimen, eradication, Helicobacter pylori infection.
Article Details
References
2. Nguyễn Thị Thảo (2017) Hiệu quả phác đồ LAL trong điều trị tiệt trừ Helicobacter pylori ở bệnh nhân viêm, loét dạ dày - tá tràng. Luận văn chuyên khoa II.
3. Trần Thị Khánh Tường (2017) Hiệu quả điều trị của phác đồ 4 thuốc có Bismuth trong điều trị nhiễm Helicobacter pylori. Tạp chí Khoa học Tiêu hoá Việt Nam 49, tr. 3067-3073.
4. Chen PY WM, Chen CY et al (2016) Systematic review with meta-analysis: The efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther 44: 427-437.
5. Evrim Kahramanoğlu Aksoya FPcS, Zeynep Göktaşb Metin, Uzmana Yaşar Nazlıgüla (2017) Comparison of Helicobacter pylori eradication rates of 2-Week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth quadruple therapy as a first-line regimen. Med Princ Pract 26: 523-529.
6. Gisbert JP RM, Gravina AG et al (2015) Helicobacter pylori second-line rescue therapy with levofloxacin and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 41: 768-775.
7. Liao J ZQ, Liang X et al (2013) Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 18: 373-377.
8. Malfertheiner P, Megraud F, O’Morain et al (2017) Management of Helicobacter pylori infection the maastricht V/ florence consensus report. Gut 66: 6-30.
9. Phan TN, Santona A, Tran VH, Tran TNH, Cappuccinelli P, Rubino S et al (2015) High rate of levofloxacin resistance in a background of clarithromycin-and metronidazole-resistant Helicobacter pylori in Vietnam. International journal of antimicrobial agents 45(3): 244-248.
10. Su J ZX, Chen H et al (2017) Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Medicine (Baltimore) 97: 5859.
Article Sidebar
